Northern Trust Corp Has $2.23 Million Stake in Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA)

Northern Trust Corp trimmed its position in shares of Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA - Free Report) by 27.8% during the 4th quarter, according to the company in its most recent filing with the SEC. The institutional investor owned 387,376 shares of the biotechnology company's stock after selling 149,329 shares during the period. Northern Trust Corp owned 1.82% of Enanta Pharmaceuticals worth $2,227,000 at the end of the most recent reporting period.

Several other institutional investors and hedge funds have also recently added to or reduced their stakes in ENTA. China Universal Asset Management Co. Ltd. purchased a new position in Enanta Pharmaceuticals during the 4th quarter worth approximately $26,000. AlphaQuest LLC grew its holdings in shares of Enanta Pharmaceuticals by 16.4% during the 4th quarter. AlphaQuest LLC now owns 22,260 shares of the biotechnology company's stock valued at $128,000 after acquiring an additional 3,137 shares in the last quarter. Thrivent Financial for Lutherans purchased a new position in shares of Enanta Pharmaceuticals during the 4th quarter valued at $254,000. Intech Investment Management LLC purchased a new position in shares of Enanta Pharmaceuticals during the 4th quarter valued at $58,000. Finally, American Century Companies Inc. grew its holdings in shares of Enanta Pharmaceuticals by 10.5% during the 4th quarter. American Century Companies Inc. now owns 36,962 shares of the biotechnology company's stock valued at $213,000 after acquiring an additional 3,501 shares in the last quarter. 94.99% of the stock is currently owned by hedge funds and other institutional investors.

Enanta Pharmaceuticals Price Performance

Shares of ENTA stock traded up $0.05 on Wednesday, hitting $5.87. The company's stock had a trading volume of 44,679 shares, compared to its average volume of 284,309. Enanta Pharmaceuticals, Inc. has a fifty-two week low of $4.09 and a fifty-two week high of $17.24. The firm's fifty day moving average price is $5.40 and its 200-day moving average price is $6.36. The stock has a market capitalization of $125.48 million, a price-to-earnings ratio of -1.19 and a beta of 0.81.

Enanta Pharmaceuticals (NASDAQ:ENTA - Get Free Report) last released its quarterly earnings data on Monday, May 12th. The biotechnology company reported ($1.06) earnings per share (EPS) for the quarter, missing the consensus estimate of ($1.04) by ($0.02). Enanta Pharmaceuticals had a negative net margin of 157.57% and a negative return on equity of 75.53%. The business had revenue of $14.93 million during the quarter, compared to analyst estimates of $15.96 million. Analysts predict that Enanta Pharmaceuticals, Inc. will post -4.65 EPS for the current fiscal year.

Wall Street Analyst Weigh In

Several research firms have recently commented on ENTA. HC Wainwright restated a "buy" rating and set a $18.00 price target on shares of Enanta Pharmaceuticals in a report on Tuesday, February 11th. JMP Securities restated a "market outperform" rating and set a $21.00 price target on shares of Enanta Pharmaceuticals in a report on Tuesday, February 11th. Finally, Wall Street Zen upgraded shares of Enanta Pharmaceuticals from a "sell" rating to a "hold" rating in a report on Wednesday, February 19th. One investment analyst has rated the stock with a sell rating, one has assigned a hold rating, three have issued a buy rating and one has assigned a strong buy rating to the stock. According to MarketBeat, the stock presently has an average rating of "Moderate Buy" and a consensus price target of $17.25.

About Enanta Pharmaceuticals

Enanta Pharmaceuticals, Inc, a biotechnology company, discovers and develops small molecule drugs for the treatment of viral infections and liver diseases. Its product pipeline comprises EDP-514, which is in phase 1b clinical development for the treatment of chronic infection with hepatitis B virus or HBV; EDP-938 and EDP-323, which is in phase II clinical development for the treatment of respiratory syncytial virus; EDP-235, which is in phase II clinical development for the treatment of human coronaviruses; and Glecaprevir, which is in the market for the treatment of chronic infection with hepatitis C virus or HCV.